PicoCELA (NASDAQ:PCLA) Rating Increased to Hold at Wall Street Zen

PicoCELA (NASDAQ:PCLA) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings upgraded shares of PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

PicoCELA Stock Up 4.2%

NASDAQ:PCLA opened at $5.41 on Friday. The business’s 50-day moving average price is $5.51 and its two-hundred day moving average price is $4.44. PicoCELA has a twelve month low of $1.35 and a twelve month high of $19.50.

Institutional Investors Weigh In On PicoCELA

A hedge fund recently bought a new position in PicoCELA stock. Jane Street Group LLC purchased a new position in shares of PicoCELA Inc. (NASDAQ:PCLA) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned about 18.92% of PicoCELA as of its most recent SEC filing.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.